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Abstract 
Background: 
Globally Regulators have been under scrutiny for delays in Market Application (MA) approvals.  The main issue 
that surfaces in studies related to these delays is a shortage in competent reviewers. The concept of a Third 
Party Assessor (TPA) who performs pre-market approvals is introduced, one who will be providing assistance to 
the National Medicine Regulatory Authority (NMRA), therefore functioning on the principle of Public Private 
Partnerships (PPPs).  The aim of this professional body would be to decrease dossier review time, increasing the 
availability to medicine, medicine-related products and medical devices that comply with quality, safety and 
efficacy standards to treatment programs in a shorter time. 
Methods: 
The study was designed around a mixed-method approach using quantitative and qualitative research methods 
to evaluate the concept of a TPA providing a support function to the NMRA.  The qualitative arm comprised of 
two sections namely assessing key factors, advantages and disadvantages of international health models (n=7) 
and PPPs (n=12). The quantitative arm analysed a regulatory professional-targeted survey (n=26) which assessed 
the susceptibility of the TPA concept, while evaluating critical factors such as what the main reasons (considered 
by participants) are for the backlog, if SAHPRA will be able to provide permanent relief to the backlog, what the 
expected time for reviewing an application is, etc.  
Results: 
The study confirmed that a lack in regulator resources is the main reason for delayed MA reviews and that an 
improved strategy is needed.  The viability of the TPA-concept was supported by 75% of the respondents, and all 
respondents confirmed that implementing a TPA will reduce the review time.  The optimal review time 
confirmed by frequency tables for New Chemical Entities (NCEs) and generic product applications were 12 - 24 
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months and 12 months respectively.  The years-experience variable was compared using Chi-Square test and 
symmetrical values, and no significant correlation was found (p>0.05).   
Triangulation with international health models and PPPs showed consistency in the advantage of reduced time, 
and the requirement and benefit of skilled resources.  The findings were inconsistent for constant 
communication and its effect on bias and transparency, and if such a partnership should ensue as a phased 
approach.   
Conclusion: 
The study concludes that optimal review times will exist if NMRAs make use of a skilled TPA.    The study also 
found that the benefits are not restricted to better timelines and an increased capacity, but that efficiency, 
performance, skills, innovation, and superior outcomes may possibly be increased as a result of a PPP. Further 
research would be needed to validate this concept and overcome this study’s limitations which included a small 
sample size.  
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Chapter 1: Introduction  
Medicine Regulatory Authorities (MRAs) have the arduous responsibility to ensure that medicine, medicine-
related substances and medical devices (MDs) approve of quality, safety and efficacy.   To successfully fulfill this 
role; time, dedication and skill are required from reviewers.  Technological advances enable innovative medicinal 
products (or New Chemical Entities [NCEs]) and medical devices, where patient access to low cost treatment, 
and pharmaceutical competitiveness encourage more generic Market Applications (MAs) to be submitted for 
approval.  MRAs form part of National Health Departments and compete for funds within the healthcare system. 
While MRAs play an important role in the healthcare system, funds are often more urgently allocated to more 
directly pressing needs such as providing medical assistance to facilities treating sick members of the population.  
The limited MRA-human and financial resources result in an imbalance from the increased submissions and time 
needed for MA reviews, which causes stakeholder tensions and a delay in optimal treatment.  
The concept of a Third Party Assessor (TPA) is introduced in this study to perform pre-market approval of 
dossiers. The intention is for this professional body to supply a support function to the National Medicine 
Regulatory Authority (NMRA), functioning on the principle of a Public Private Partnerships (PPP), which is the 
cooperation between the government and private entities.  The aim of this professional body would be to 
decrease dossier review time, making medicine, medicine-related products and Medical Devices (MDs) that 
approve of quality, safety and efficacy available to treatment programs, in a shorter time. 
The South African Medicines Control Council (MCC) is considered one of the most competent MRAs on the 
African continent, yet severe delays in MA reviews and approvals have existed for many years (Board on Health 
Sciences Policy, 2012:44), even after aligning with ICH’s regulatory harmonization standards and guidelines, and 
using CTD and eCTD dossier formats.  The current process followed (as seen in Figure 1) makes use of the limited 
and often temporary MCC staff (see Appendix 2 for the current MCC structure) and committee members  
(Figure 2). 
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Figure 1: MCC Registration Process (Taute, 2014: 4) 
 
Figure 2: MCC and Expert Committees (MCC, 2003-2013) 
The TPA who will act as an extension of the MCC/SAHPRA in terms of responsibility, and independent from the 
industry to avoid bias, will be a company led by a CEO, driven by performance appraisals (Appendix 3: TPA 
Organogram).  The process as seen in Figure 3 (and outlined in Appendix 4 where the process is described) will 
ensure that the screening and review is done by the Expert Reviewers (ERs) within a pre-established timeframe. 
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Figure 3:  Registration process using the Third Party Assessor 
This study confirmed that only one TPA (and not various contracted TPAs) should exist based on exploring 
benefits and criticism of Notified Bodies (NBs).  NBs are private commercial entities licensed by national medical 
device regulators under the legal framework of Directives 90/385/EEC, 93/42/EEC and 98/79/EC, and are 
responsible for evaluations and inspections of medical devices in the European Union (EU) to assign 
Conformance approvals (CE-marking) before it can be marketed.  Other international health models that provide 
assistance to the NMRA structures and operations also explored in this study are: 
 Accredited Person Program (APP) / Third Party Program (TPP) for medical devices, part of the FDA’s 
Modernization Act of 1997; 
 Generic Drug User Fee Act Program (GDUFA) for generic products jointly proposed by the FDA and industry; 
 Prequalification Programme of the WHO focusing on vaccines and medicines for third world-related 
epidemics such as HIV/AIDS and malaria; 
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 Article 58 of the European Medicines Agency’s (EMA) Regulation (EC) No 726/2004 for WHO targeted 
diseases;  
 FDA’s Tentative Approval of generic anti-retrovirals that expedites the availability of generic products; and 
 European Benchmarking Agency for setting standards, sharing best practices and identifying areas for 
improvement. 
The survey that was done as part of this study to explore the susceptibility of the TPA concept investigated if a 
shortage in reviewers is the main reason for the backlog, if an improved strategy (other than SAHPRA replacing 
MCC) is needed to eliminate the review backlog, whether TPA is considered a viable option and ultimately if 
optimal review times will come into effect if a skilled TPA is introduced. 
The study also compared what participants considered as imperative roles the TPA should play and illustrates 
the advantages and disadvantages of the different types of international health models listed above as well as 
PPPs (not limited to the health sector). 
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Chapter 2: Literature Review  
2.1. Introduction 
In an era where technology rapidly advances and an escalating health demand exists, with an increasing life-
expectancy of the global population and luring epidemics in developing countries such as malaria and HIV/AIDS, 
the responsibilities of National Medicine Regulatory Authorities (NMRAs) increase substantially to ensure that 
safe and efficacious medicines and medical devices that meet quality standards reach the patient in time. MRAs 
have been under scrutiny for delayed MAs worldwide. 
2.2 Optimal Review Times 
2.2.1. International Review Times 
When considering a country’s MRA responsibilities, a starting-point would be to look at the definition of 
Regulatory Science.  The US Food and Drug Administration (FDA) Science Board defined it as the assessment 
process a public health organisation follows, utilizing scientific staff and resources to expand the evaluation and 
monitoring capacity, and to modernize and develop new regulatory pathways (FDA Science & Technology 
Subcommittee, 2007).  This report highlighted that the ratio between resource- and demand-increases were 
disproportionate, similar to the statement made by South Africa’s Registrar, reasoning the backlog experienced 
as a result of evaluators and committee member-amounts being equal to those appointed in 1965 (Thom, 2010).   
In the book, Building a National Framework for the Establishment of Regulatory Science for Drug Development 
(US National Academy of Sciences, 2011), Prof. FitzGerald, Director at the Institute for Translational Medicine 
and Therapeutics, pertinently excluded methods to accelerate approval from the definition in his guidelines, yet 
the time it takes for the Regulator to give feedback plays a vital role in the wellbeing of the country’s health 
sector and population.  The essence lies in not compromising quality or safety during accelerated reviews, but 
adhering to predetermined and optimal timeframes.  The time-balance required is delicate between proving 
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safety, making needed treatment accessible to patients and recovering R&D expenditures.  Alexander et al. 
(1991) already discussed the effect on patent life and market entry more than 2 decades ago, with fluctuations 
in approval times as seen in Figure 4, with the spike observed in the 60’s due to the emphasis on safety and 
efficacy.  Delays during this 30-year period were due to a shortage in the Regulator’s human resources and the 
quality of applications to proof safety and efficacy.   
 
Figure 4: Duration of drug approval process in US between 1960 and 1990 (Alexander, 1991) 
A comparison done on the MA approval process time internationally showed that India required the least time, 
32-48 days, and the UK’s Centralised procedure the most time (of the five countries compared), with 210 days. 
Table 1: Comparison of the time required in the drug approval process (Dureja, 2010) 
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Melchior’s study (2011) on the transparency of Regulatory Agencies (RAs) showed that the FDA was 90% within 
its performance goal, a drastic reduction from data in Figure 4: 
Table 2:  Summary of FDA’s annual review time and performance goals between 2008 and 2012 (Melchior, 
2011: 8) 
 
The study also concluded, based on EMA’s 2009 Annual report, that 99% of Market Applications (MAs) were 
assessed within its 210-day review time. The significance seen in this is that although EMA subjected themselves 
to a more extended time (in Dureja’s comparison between the five countries, Table 1), they were the most 
compliant as seen in this study. New Chemical Entities’ (NCE) review times for MRAs which also includes Japan, 
New Zealand and Canada are summarised in Figure 5. 
 
Figure 5: An overview of NCE review timelines for different MRAs (Melchior, 2011: 19) 
A recent publication by Davis and Abraham (2013) showed that pharmaceutical companies submitting 
incomplete and substandard MAs to the FDA were mainly responsible for review-time delays. 
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In published literature on a workshop summary, FDA Commissioner Margaret Hamburg (2013) expressed the 
importance of partnerships for a sustainable regulatory infrastructure, rightfully stating that strategies and 
standards must be harmonized, and that resources will be critical to identify priority areas to ultimately achieve 
an improved regulatory science.  
Dr Bernard Pécoul (2010) stated that a Drugs for Neglected Diseases initiative (DNDi) workshop revealed that 
capacity deficiencies impeded access to much needed treatment.  The six main causes identified a lack of:  
 Unambiguous legislative framework; 
 Financial resources; 
 Experienced and qualified workforce; 
 Political assistance; 
 Stakeholder appreciation; and 
 Distribution of regulatory responsibility resulting in neglected areas.  
Different regulatory approaches were discussed and rated as seen in Table 3 and a useful action map (Figure 6) 
which may assist NMRAs determine the urgency, complexity and resource efficiency on a national to global level 
in terms of capacity. 
Table 3: Alternative regulatory approach performance table for NTDs (Moran, 2010: 22) 
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Figure 6: DNDi action map of regulatory capacity-building investments and activities (Moran, 2010: 25) 
Limitations to the value of the data in this study lies in the fact that it focused on NTDs (Neglected Tropical 
Diseases) and on the African continent as a whole.   The alternative approaches discussed remained options, are 
used preferentially by developers, and may require repeated or duplicate reviews (by either WHO or Western 
MRAs), not making it optimal.  The study acknowledges that the medicine discussed may only be required by a 
small percentage of the Western population, and made proposals from a stakeholder perspective to manage 
limited regulatory resources and reinforce MRAs as seen in Figure 6.   
Dureja’s comparison of the drug approval process (as discussed above) concluded that the steps taken by the 
ICH towards harmonised guidelines, requirements, interpretations and applications of it will reduce duplication 
of work.   
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2.2.2 National review times: South Africa 
On national level, suboptimal review-timelines were said to be due to both Medicines Control Council (MCC) 
inefficiencies and substandard applications from pharmaceutical companies.  The backlog grew year on year as 
seen in Figure 7. 
 
Figure 7: MCC registration backlog 2003-2007 (Thom, 2010)  
In 2008 the ‘Backlog Project’ reduced the 4500 application-backlog (with submissions from 2001) to 1500 (by 
June 2010), however the support of the Department for International Development (DFID) (SARRAH, 2010).  In 
2013, 26 evaluators were contracted to accelerate generic registration during the first quarter (SARRAH, 2013).  
This lead to the problem of using a reactive approach by involving external reviewers, increasing costs, causing 
inconsistent reviews and uncertain review timeframes, which is not a sustainable long-term solution – a 
proactive approach is required. 
Motsoeneng (2012) reported that it takes up to 60 months for a product to reach the market and costing some 
pharmaceutical companies up to 3 billion Rand of losses per year in South Africa. Dr Seoka (2012) acknowledged 
that the delay in medicine registration is unacceptable and that caution must be exercised against short-term 
solutions in trying to increase MRA capacity.  She however argued in favour of national independence while 
building capacity, and stated that some facts in a dossier may have been overlooked by one country’s MRA that 
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is picked up by another.  This is in agreement with Dr Pécoul’s statement (also discussed above – p22) that 
different clinical data will be required and assessed for different populations, and that an appropriate risk-
benefit assessment with regard to specific populations will be reliant on the local MRA even if more stringent 
MRAs exist elsewhere (Moran, 2010).  Dr Seoka supported cooperation and building partnerships.  A possible 
gap may be the lack of effective communication between MRAs globally, granting each other access to 
documentation regarding the decision-making process of specific products, on request, while agreeing to public 
non-disclosure.   
In an interview with the Registrar (Thom, 2010) Ms. Hela stated that two of the main setbacks were the number 
of temporary staff currently employed at the MCC (which will be replaced by permanent staff with the 
introduction of SAHPRA) and that a “Tsunami of generics” were submitted and very few NCE submissions. 
 
Figure 8: Amount of generic and NCE applications between 2003 and 2007 (Thom, 2010) 
Some of the benefits of harmonization and the global use of CTD and eCTD are the increased transparency and 
reduced time in the review and approval process (Molzon, 2010).  In SA the pilot project for eCTD is in the final 
stages, but teething problems were experienced and more applicant-training is needed.  Expectations of a more 
effective NMRA and a closer working relationship with the local pharmaceutical industry (in terms of 
0
100
200
300
400
500
600
700
800
900
2003 2004 2005 2006 2007
16 27 18 21 22 
508 
563 
490 
801 765 
A
m
o
u
n
t 
o
f 
A
p
p
lic
at
io
n
s 
Year 
NCE applications
Generic applications
 
 
 
 
26 
 
regulations), are channeled towards SAHPRA, who will replace the MCC, and will operate outside of the existing 
public service, but report to the Minister of Health (Minister of Health, 2014).  It was expected to be in place by 
April 2013, but latest reports indicate that SAHPRA will effectively take over towards end 2014 (Bateman, 2013). 
SAHPRA will have 400 instead of 150 members (Reuters, 2012), and the submission costs will increase, but the 
newly published CAMS regulations (requiring a similar process as medicine approval) (MCC, 2013), and its local 
industry worth R8.5 billion (HPA, 2013) will necessitate increased and competent assessors.  The CAMS 
regulations also increase applications towards category A (allopathic medicine), which previously fell outside this 
category.  Furthermore, the medical device and IVD (In Vitro Diagnostic Medical Device) licenses in SA relied on 
the EU’s CE certification (Arazy, 2013), but the new draft regulation was published in April 2014 which will 
necessitate an additional increase in MRA-capacity. According to the Amendment Bill (2014: 4) the Authority 
(referring to SAHPRA) is responsible for the regulatory oversight of cosmetics, foodstuffs and hazardous 
substances.  Regulations for cosmetics, disinfectants and food products will also be implemented according to 
plan in the near future, all of which will further increase the regulatory burden.  New technologies e.g. stem 
cells, advances in biological products, etc. will also require regulatory control, so the demand on the limited 
resources will grow. 
 
The concern remains if the new MRA will be able to accommodate all dossiers and ensure timely reviews.  In the 
UK the Medicines and Healthcare Products Regulatory Agency (MHRA) makes use of Notified Bodies (NBs) for 
medical device audits and MA reviews (MHRA, 2013), the FDA of Third Party Programs (TPP) for medical devices 
by Accredited Persons (FDA CDRH, 2001) and Tentative Approval for generic ARVs (FDA, 2013).  The WHO’s 
Prequalification Programme focuses on vaccines and medicines for third world-related epidemics such as 
HIV/AIDS and malaria (WHO, 2011) and the European Benchmarking Agency for setting standards, sharing best 
practices and identifying areas for improvement.   
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The Amendment Bill makes allowance for SAHPRA to liaise with any other regulatory authority or institution for 
matters of common interest and to enter into agreements of cooperation.   It also confirms that one of its 
objectives is to ensure a timeously evaluation and registration process (2014: 4). 
2.3 Research Question 
Will the MRAs review time for Market Applications decrease if a permanently appointed, competent Third Party 
Assessor is used, who is trained by an MCC/SAHPRA accredited trainer and program? 
2.4 Hypothesis 
If MRAs make use of a skilled Third Party Assessor, optimal review times for Market Applications will exist.   
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Chapter 3: Methodology  
The study was designed around a mixed-method approach using quantitative and qualitative research methods 
to evaluate the concept.   
3.1 Qualitative Analysis 
The qualitative component of the study followed the methodology of grounded theory leading to categorization 
of data, namely coding, which is considered as the essential analytical process rather than a segment of 
qualitative research (Corbin and Strauss, 1990).  This iterative approach provided structure to the TPA-concept, 
in support of proving or disproving the hypothesis.  During the initial step, namely open coding, the following 
categories for this study were constructed, which compared international models using the concept of 
mediators in the market application review process: 
   Market application category; 
   Purpose/Primary role; 
   Scope of practice; 
   Assessed by; 
   Criteria for designation/Qualification standards/Requirements; 
   Advantages; 
   Criticism; and 
   Unique, beneficial initiatives. 
Public Private Partnerships’ (PPPs) advantages and disadvantages were coded and evaluated and during the 
second step, axial coding, the relationships between the international models in the health sector and PPPs (not 
limited to the health sector) were assessed, investigating integration and correlations between the categories 
(Walker, 2006).   
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The core category of the study, namely establishing if optimal review times will exist if a TPA (or mediator) is 
employed (proving or disproving the hypothesis), emerged from the final step, namely selective coding, where 
the other categories were related to the principal categories of review times and permanently appointed, 
trained and competent staff. 
A significant property of grounded theory is theoretical sampling (Charmaz, 2006), where a deeper 
understanding is obtained of the concepts explored.  It is essential in this research as the concept of a TPA is new 
and has never been explored before, meaning that investigating concepts similar to this is fundamental to 
establish a foundation for this theorized body.  Theoretical sampling is also an important method for 
triangulation, again supporting this study as independent data was collated and compared to increase 
comprehension of an unfamiliar and new concept. 
3.2 Quantitative Analysis 
The quantitative arm of the study was a survey distributed via email to members of the South African Regulatory 
industry.  This was done to assess the susceptibility of the concept of a TPA and to evaluate the factors 
considered as important by this population (in the light of a TPA), the optimal review time for New Chemical 
Entities (NCEs) and Generic product applications, the main reasons for the current backlog and most 
importantly, if a TPA would reduce the review time of dossiers from submission to market approval.  In South 
Africa the Regulatory professionals belong to the South African Pharmaceutical Regulatory Affairs Association 
(SAPRAA), which has a total of 250 members.  The total amount of survey respondents (n=26) formed part of the 
inclusion criteria and voluntary completed the questionnaire.  Individuals from the pharmaceutical sector that 
formed part of the exclusion criteria were those not directly involved in the regulatory process e.g. retail 
pharmacists, hospital pharmacist, recruiters etc.  Actual respondents consisted of: 
 Regulatory Pharmacists; 
 Consultants; 
 Quality Assurance Pharmacists / Quality Compliance Pharmacists / Quality Assurance Officers; 
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 Regulatory Pharmacist Assistants / Regulatory Affairs Assistants; 
 Directors; 
 Legal Advisors; and 
 Regulatory Food Scientists. 
No NRA-members participated in the survey which reduced unbiased results. 
Although probability sampling is considered to be the superior sampling method to keep sampling error to the 
minimum, to be a true representation of the population, and to decrease bias while increasing generalisation 
and validity (Brennan, 2013), it was not possible to sample via this route for this research project.  The study 
made use of non-probability sampling for the survey, as the survey was distributed to the population of national 
regulatory professionals via email, of which the sample is considered those who were willing to complete the 
questionnaire.  For ethical conformity a disclaimer was added to the survey email to ensure that participants 
were aware that they voluntarily participate in the anonymous survey and were allowed to withdraw at any time 
(refer to Appendix 5). 
The main variable of the questionnaire considered was the years experience in the Regulatory field.  Methods 
included descriptive statistics, Spearman’s rank order correlation, Pearson’s chi-square to test the relationships, 
and Phi/Cramer’s V to test the strength of the relationship and the practical significance (Ellis, 2003).   Data were 
analysed using Excel, correlation tests (non-parametric) and categorical testing (crosstabs) were done using the 
Statistical Package for the Social Sciences - SPSS 21.0.0 (2013).  The Mann–Whitney test was not used due to the 
small sample size (not being a true representative sample of the population) and the sample sizes between <5 
years experience and >5years experience not being equal in size. 
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This cross-sectional survey was made available to the study population at a particular time point (one 
questionnaire per participant from the survey which was available for a month).  Groups that were compared 
within the sample comprised of categorical/nominal variables (job titles within the regulatory field, years 
experience) compared with ordinal/quantitative variables (using the ranking of what is considered as important 
if a TPA are to be included in the review process – see Appendix 6 question 6).  The space created in the 
questionnaire for general comments or thoughts on the TPA-concept (question 9) and question options of 
‘Other’ (where it was requested to specify if this option was selected), allowed confounding variables to surface.  
Although not optimal, this was used purposefully to enrich results and ensure that all variables are considered to 
successfully establish the need of - and construct a desired body to provide relief to the current dossier review 
dilemma experienced and to be of benefit to the regulatory industry as a whole.   
The data from this questionnaire feedback was quantified to produce conclusions that can be generalised to a 
certain extent (Bell, 2010: 5).   
3.3 Mixed Method Analysis 
The data from the qualitative and quantitative arm of the study were used to attain an insight and appreciation 
of the local regulatory industry’s perception of the TPA-concept. This form of exploratory research allows for 
new discoveries and minimise the probability of rejecting relationships that might exist.  As the research 
problem, namely what the effect of the NMRA’s review time will be if competent TPAs are used, has no similar 
studies to refer to, the exploratory approach assist in generating this new concept and assumptions, testing its 
feasibility, and assist in establishing  what the research priorities are.  Disadvantages to this design are the 
difficulty to generalize the results, data may seem unstructured and are difficult to draw a definitive conclusion 
(Labaree, 2013). 
Methodological triangulation, which entails using qualitative and quantitative study methods, was used to add 
validity to the concept by testing if the two sets of results obtained was consistent and increase confidence in 
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the conclusions (Guion, Diehl and McDonald, 2011).  A disadvantage to this method is that new lines of enquiry 
emerged.  An example of this was the structure of the TPA in terms of management – being a company with a 
CEO, or following the structure of Partners (as seen in law or consulting firms) which enjoys the benefit of 
ensuring that diligence remains in the proposed company and that the lack of competition would not cause 
indolence and returning to a review backlog again.  The concept however was designed around a CEO (refer to 
the organogram in Appendix 3).  Other disadvantages of triangulation are not only the increased time-
consumption and planning that is required, but that the results may diverge.  Although this may be considered 
as disadvantageous, theories can only be developed more and on a deeper level if challenged to obtain a more 
unambiguous concept by exploring through innovation to overcome inconsistencies.    The study also made use 
of theoretical triangulation in the survey by using participants from different positions within the regulatory 
discipline that gave feedback from different perspectives.  This was guided by the inclusion criteria of the 
questionnaire (refer to Appendix 6 question 1) these professionals in the regulatory sector would influence 
feedback and decrease bias. 
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Chapter 4: Findings, Analysis and Discussion 
4.1 Qualitative Analysis 
 
4.1.1 Establishment and Purpose  
In the formulation of the TPA-framework, international health bodies (n=7) that form part of a third party or 
alternative regulatory program were explored to determine the need or gap that existed, fulfilling its primary 
purpose for its establishment: 
 Notified Bodies (NBs) 
NBs were established in the early 1990’s from a form of self-regulation as a result of conscientious 
manufacturers assessing medical devices (MD) and the quality of systems, developing into EU legislation.  
This allowed these bodies to grant pre-market approval using a recognised regulatory procedure. This 
delegation was mainly due to the lack of MRA resources in relation to MD regulation, to enable 
assessment of MD-conformity. The international review timelines depending on the type/class MD are 
one to 36 months (see Appendix 7). 
 
 Accredited Persons Program (APP) / Third Party Program (TPP) 
The original purpose for this program was to reduce cost to stakeholders, yet after the FDA’s 
Modernization Act (FDAMA) was signed into law in 1997, the agreement to have Accredited Persons 
(APs) perform specific FDA tasks on its behalf for MDs, reduced the inspectors’ burden while ensuring 
compliance with regulatory requirements.  Fulfilling the purpose of prompt decisions while ensuring 
confidence in the APP, the scope of practices were divided to have the APs assess low to moderate risk 
MDs while the FDA continued assessing high-risk devices.  The approval process takes an average of 72 – 
109 days (see Appendix 8). 
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 Generic Drug User Fee Act Program (GDUFA) 
Implemented in 2012, with the aim on safety, access and transparency, GDUFA was established to 
provide additional human resources, to ensure that patients receive faster access to quality medicine 
that is inexpensive, to further provide increased predictability with regard to timelines and the review 
process for generic products.  The FDA uses a risk-based method to inspect GDUFA biennially and this 
allowed them to perform their vital purpose using FDA freed-up resources.  The stipulated timeline for 
this process is 10 months (see Appendix 9). 
 
 Tentative Approval (TA) 
TA was designed to accelerate generic medicine availability for PEPFAR (the President’s Emergency Plan 
for AIDS Relief) and took effect as an accredited FDA review process in 2004. TA indicates that the 
product meets standards of safety, efficacy and manufacturing quality. MAs were welcomed from 
international applicants for single ingredient, fixed-dose combination (FDC) and co-packed ARVs.  With 
quality submissions, the target review time of two to six weeks are met. 
 
 WHO’s Prequalification Programme (WHO PQP) 
The WHO PQP has facilitated developing countries in enhancing their regulatory capacity through 
regulator engagement and training.  The programme first focused on quality vaccines (1987), expanding 
to include medicines from 2001.   PQP focus on preventing scientific assessment duplication using a 
condensed review process for products already approved by recognised MRAs e.g. EMA and FDA. The 
mission of PQP is to increase the availability of quality medicinal products to patients. The median time 
determined in 2010 for prequalification approval of generic and innovator products were 4.3 and 31.6 
months (WHO, 2011). 
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 Article 58 
Laid down by the European Parliament in 2004 (Regulation (EC) No 726/2004), Article 58 was 
established in response to protecting public health and in support of WHO, to provide timely access to 
medicinal products.  The review process is aligned with the standard regulatory MA review, but the 
EMA’s CHMP (Committee for Medicinal Products for Human Use) gives a scientific opinion and advice 
instead of final approval.  The rapid, yet thorough process takes an average of 2.5 months (Appendix 10). 
 
 Benchmarking of European Medicines Agencies (BEMA)  
BEMA was established in 2004 following UK and Germany’s proposal of implementing a benchmarking 
project for human and veterinary MRAs, where standards would be set, gaps identified and best 
practices shared in the public and private sector to encourage performance improvement.  BEMA is a 
collective approach between NRAs and consultants fulfilling EC-legislative responsibilities, augmenting 
self-assessment (BEMA, 2012: 8). Part of BEMA’s aims is to supplement the decision-making processes 
with pragmatic intelligence, while increasing transparency and responsibility during the approval 
process. 
A trend observed from these bodies is that a regulatory partnership was established after a need was identified 
within the regulatory process, to enable an increase in available resources for regulatory responsibilities and to 
reduce the time spent on assessments, ensuring increased compliance, transparency and performance, and to 
ultimately accelerate the availability of a quality product to the patient population. 
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4.1.2 Advantages 
The advantages of the international health models (n=7) were assessed, coded and compared.   
 
Figure 9: Percentage of international models with comparative advantages  
 
From the data in Figure 9 it is evident that 86% of the bodies present the benefit of reducing the time spent 
towards approvals, as well as an increase in the available resources and the regulator’s capacity, reducing the 
assessment burden, which leads to a further benefit of making MRA-resources available to perform their other 
critical functions.  The third highest benefit from the study showed that the third party bodies act in favour of 
public interest, increasing earlier patient access to medicinal products. 
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When this data was compared with the benefits for Public Private Partnerships (PPPs) recorded in the literature 
(n=12) commonalities were observed.  During the ‘Post-2015 Development Agenda: Setting the Stage’ UN 
General Assembly, John Sanbrailo, Executive Director of the Pan American Development Foundation (2013) 
supported  that PPPs provide a unique answer to hurdles countries face, especially for partnerships with shared 
objectives and accountability, and synergistic interactions and decision-making.  In a PPP workshop held on food 
and nutrition (Pray and Pillsbury, 2012), it was concluded from participants feedback that complex societal 
health issues can be addressed successfully during public-private collaborations where resources, skills and 
perspectives are employed in unison. 
 
Figure 10: Percentage of PPPs’ advantages per category 
It is apparent from Figure 10 that the majority of the benefits from a PPP are collective, with collaborative 
strengths peaking at 92%, followed by 83% for being cost effective, PPPs resulting in increased efficiency and 
performance, as well as increased ownership, accountability and a shared benefit-risk responsibility. 75% 
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reported shorter project delivery times and are favoured for its increased resource availability to perform its 
functions.  
Important from these findings is that with the reduced costs and waiting time, PPPs still owned the advantage of 
adding value and delivering high quality projects, to further provide a positive impact in favour of public interest.  
The benefits of transparency and technological advance were parallel to the findings from Figure 9, with results 
below 20%. 
A process-flow can be established by combining the positive correlations between Figure 9 and 10 in Figure 11: 
 
Figure 11: A process-flow stipulating the progression of benefits with a partnership agreement 
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4.1.3 Concerns and disadvantages 
In order to successfully construct the TPA concept, the concerns around - and disadvantages experienced with 
the International Health models and PPPs were considered.  Table 4 depicts these challenges: 
Table 4: Concerns and possible disadvantages of intermediary models currently in operation 
 
Concerns around PPP’s were mainly finance-related (which directly relates to bias), but also included complex 
contracts and negotiations, risk-baring, potential imbalance in data access, intercompany culture gaps, short-
term rigidities, and a lack of competition causing inefficiencies in the long-term. 
The disadvantage of favouritism observed for NBs are due to the fact that a large number of these bodies are in 
existence, where applicants have the freedom of choice which NB to use and can change to a different NB in the 
case of a MA rejection. Some NBs have been involved in the MD-development, which causes conflict of interest, 
and the financial drive of both parties, together with market competition have caused bias.  This process defect 
encouraged substandard assessments, which means poor quality and unsafe MD’s were approved.  
Standardization of the review process by the Advanced Medical Technology Association (AdvaMed) and 
European Commission (EC), tightened regulations and a Code of Conduct were applied with strategies to 
improve consistency, competency and objectivity during assessments.  This highlighted the importance during 
the construction of the TPA-concept to have a single TPA-entity, which would act as an extension of the NMRA, 
to eliminate bias and conflict of interest. 
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Favouritism seen in PPPs was mainly due to the fact that a partnership exists on a temporary contract basis.  The 
issue of temporary staff was also emphasized by the MCC Registrar (as discussed in Chapter 2) as being one of 
the main setbacks leading to the review backlog experienced.  The international health bodies discussed above 
were all adopted into the relevant countries’ legal framework, which eliminated the temporary staff-factor, and 
also supports the appointment of permanent staff.  This approach would be applicable to the TPA structure and 
partnership with the MRA.  
This may lead to the next concern of a lack of competition causing inefficiencies in the long-term (as seen above 
with PPPs).  Yet, with the overwhelming existence of new applications and the inexhaustive demand from 
industry for MA reviews and approvals, in addition to pre-established review timelines, TPA efficiency and 
performance will be assured.  This also signifies the value of the TPA being a registered company driven by 
performance appraisals (as discussed in Chapter 1) to ensure competent staff and institutional integrity. 
With the introduction and implementation of new initiatives, short-term rigidities and challenges (as seen with 
PPPs) will be inevitable. This supports a phased approached, as well as comprehensive, unambiguous TPA-NMRA 
requirements and responsibilities specified in contractual and technical agreements.  Vital contractual inclusions 
will be addressing and demonstrating relationships between potential conflict of interest, transparency and non-
disclosure agreements. 
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4.2 Quantitative Analysis 
To assess the susceptibility of a TPA performing pre-approvals for the MRA and reduce the dossier review time a 
questionnaire was used (Annexure 5).   
According to the respondents (n=26) the main reason for the current backlog experienced (as seen in Figure 12) 
is that the MCC does not have enough reviewers (88%) followed by different MCC members handling dossiers 
with every resubmission (if changes are needed to the application) (32%).  
 
Figure 12: Reasons for the current backlog 
The 12% feedback received for the Other* category reported that the backlog is due to maladministration, 
political reasons, not enough experienced reviewers and MCC misplacing applications and resubmissions. 
Uncertainty remains as to when exactly SAHPRA will take over from the MCC and the Amendment Bill has given 
a basic outline to their functions and structure, as reported in the Literature Review, but is was evident from the 
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results depicted in Figure 13 that an improved strategy will be needed to provide relief to the current backlog, 
have optimal review time-frames and be compliant with these set time-frames. 
 
Figure 13: Respondent’s opinion if SAHPRA will eliminate the backlog once implemented 
The key variable considered in the questionnaire was the years’ experience the respondents have in the 
regulatory industry. It was used to assess the validity of the answers, ensuring reasonable expectations based on 
knowledge and experience.  74% of the respondents had <1 - 5 years’ experience and 26% more than 5 years 
experience in the regulatory industry. 
 
Figure 14:  Respondents years experience in the regulatory industry according to questionnaire groups 
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The participants were asked to rate the importance of eight operational aspects and qualities that would be 
considered fundamental when functioning via the TPA towards accelerated market approval, with the rating of 1 
being the least important and 10 being imperative: 
1. The TPA is audited annually by the MRA; 
2. The applicant can appeal against a decision made by the TPA and/or the MRA; 
3. The applicant can anonymously rate the TPA based on the quality service received; 
4. Transparency in decisions; 
5. Intellectual property protection (signing a Non-Disclosure Agreement); 
6. Constant communication between the applicant and the TPA; 
7. No substantial additional application costs; and 
8. Expedited reviews must still be reviewed by the MRA. 
Table 5: Analysis of the ranking of operational aspects and qualities according to importance using descriptive 
statistics 
 
It can be seen from the data in Table 5 that all eight aspects and qualities were considered important with the 
means between 7.35 and 8.83.  The highest score was for transparency in decisions with a mean value of 8.83 
(2.289), followed by the non-disclosure agreement with a mean value 8.78 (2.679) and that the applicant can 
N Minimum Maximum Mean Std. Deviation
TPA_audited_annually 23 1 10 8.09 2.843
Applicant_can_appeal_vs_TPA_decision 23 3 10 8.70 2.077
Rating_the_TPA_anonymously 23 2 10 8.13 2.546
Transparency 23 2 10 8.83 2.289
NDA 23 1 10 8.78 2.679
Constant_communication 23 1 10 7.61 3.500
No_additional_costs 23 1 10 8.26 2.832
MCC_handling_expedited_reviews 23 1 10 7.35 2.964
Valid N (listwise) 23
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appeal with a mean value of 8.70 (2.077) – having the lowest standard deviation.  Constant communication 
between the assessor, MRA and applicants received the second lowest average score 7.61 with the highest 
standard deviation (3.5), showing a higher inconsistency between the answers submitted.  This may be due to 
the idea that communication between the reviewer and the applicant may interfere with the judgement of the 
reviewer, causing bias.   Comments from respondents in this regard included that communication should remain 
at the level of the MRA and applicant, and that the applicant should not be in direct contact with the TPA.  It was 
also stated that the MRA’s logging and tracking system should enable the applicant to follow up on the status of 
the application, not allowing communication between the applicant and the TPA to eliminate corruption. 
Practical initiatives from BEMA with the focus on transparency, consistency in interaction and advice, quality, 
robustness, and encouraging good practices, included Agency Scorecards, Good Review Management Principles 
(GRMP) (Cone and Walker, 2005: 3) and key performance indicators (KPIs) (BEMA, 2012: 21).  
Interestingly, in a question where respondents were asked if the quality of the dossier submitted will increase as 
a result of this intercommunication between the applicant, TPA and the MRA, 82.6% (n=23) confirmed that the 
quality will increase.  One of the respondents stated in the comments section that the quality of the dossier 
submitted is upon the individual compiling the dossier and the standards of the company (applicant).  The 
significance in these findings considering communication are that applicants covet clear communication to 
enable their dossier submission’s quality to increase in accordance with the MRA’s expectancy, clearing 
ambiguities and unnecessary delays to effectively accelerate the process for both the reviewer and applicant.   
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Figure 15: The quality of dossier increase as a result of Applicant-TPA-Regulator intercommunication 
To assess correlations between the years experience and the answers on the importance (of each point when 
functioning via the TPA with the value 10 being imperative), the Spearman’s rho test was used for this ordinal 
data (instead of the Kendall’s tau test). 
Table 6: Spearman’s rho correlation between the years experience and the importance of the eight categories 
of Question 6 
 
Experience TPA audited 
annually
Applicant can 
appeal vs TPA 
decision
Rating the TPA 
anonymously
Transparency NDA Constant 
communication
No additional 
costs
MCC handling 
expedited 
reviews
Correlation Coefficient 1.000 .133 .063 .449
* .320 .168 -.029 .005 .234
Sig. (2-tailed) .545 .774 .032 .137 .444 .895 .981 .282
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .133 1.000 .701
** .363 .756
** .335 -.043 .168 .367
Sig. (2-tailed) .545 .000 .088 .000 .118 .847 .444 .085
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .063 .701
** 1.000 .574
**
.599
**
.618
** .243 .559
**
.505
*
Sig. (2-tailed) .774 .000 .004 .003 .002 .265 .006 .014
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .449
* .363 .574
** 1.000 .441
*
.633
** .410 .429
*
.682
**
Sig. (2-tailed) .032 .088 .004 .035 .001 .052 .041 .000
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .320 .756
**
.599
**
.441
* 1.000 .386 .210 .314 .363
Sig. (2-tailed) .137 .000 .003 .035 .069 .336 .145 .089
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .168 .335 .618
**
.633
** .386 1.000 .546
**
.606
**
.718
**
Sig. (2-tailed) .444 .118 .002 .001 .069 .007 .002 .000
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient -.029 -.043 .243 .410 .210 .546
** 1.000 .430
* .409
Sig. (2-tailed) .895 .847 .265 .052 .336 .007 .040 .053
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .005 .168 .559
**
.429
* .314 .606
**
.430
* 1.000 .723
**
Sig. (2-tailed) .981 .444 .006 .041 .145 .002 .040 .000
N 23 23 23 23 23 23 23 23 23
Correlation Coefficient .234 .367 .505
*
.682
** .363 .718
** .409 .723
** 1.000
Sig. (2-tailed) .282 .085 .014 .000 .089 .000 .053 .000
N 23 23 23 23 23 23 23 23 23
NDA
Constant communication
No additional costs
MCC handling expedited 
reviews
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
Spearman's rho Experience
TPA audited annually
Applicant can appeal vs 
TPA decision
Rating the TPA 
anonymously
Transparency
Correlations
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It is apparent from Table 6 that there is no significant correlation, with p (Sig.) >0.05, between the years 
experience and the importance of the eight categories.  The small sample size (n=23) also influences the validity 
of the results. 
To explore the dependent variable of the hypothesis, namely optimal review times for MAs, the participants 
were given an open question in the survey to state what they consider an optimal and fair review time would be 
for assessors to review new chemical entities (NCEs) and generic product applications.  From the descriptive 
analysis (Table 7) it was seen that the participants’ (n=19) opinion varied significantly. 
Table 7: Descriptive Statistics table for the minimum and maximum time considered favourable and fair for 
NCE and generic MAs 
 
By making use of Frequency tables (Appendix 8) it was found that NCEs’ desired review times are 12 – 24 
months, and generic applications 12 months.  On the histograms of these Frequency tables it is noticeable that 
the respondents have a more definite opinion of the required time of generic reviews with the histogram’s 
normal distribution (Figure 14), than for NCEs which has a positively skewed distribution (Figure 13).  The 
rationale behind this finding may be due to the fact that 70% of the current backlog is for generic applications 
allowing participants to have a better opinion considering the required review time. It may also show that 
applicants accept that NCEs have new hurdles specific to the product that may take longer or have varied review 
timeframes for the reviewers to confirm that the product approves of quality, safety and efficacy. 
N Minimum Maximum Mean
Std. 
Deviation
NCE_Min 19 3.00 62.00 20.2105 14.54716
NCE_Max 19 3.00 62.00 21.6316 15.75934
Gen_Min 19 1 36 11.68 8.718
Gen_Max 19 1 36 12.00 9.062
Valid N 
(listwise) 18
Descriptive Statistics
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The outlier observed in the results may be due to the participant’s misinterpretation of the question as the 
answer submitted was in accordance with the current time lines. 
 
Figure 16: NCE minimum and maximum review time from Frequency tables showing a positively skewed 
distribution 
 
Figure 17: Generic application review time from Frequency tables showing a normal distribution 
To assess the participant’s years experience as a variable on the outcome of the expected time-frames, 
nonparametric correlations, crosstabs, Chi-Square tests and Symmetric measures (Phi and Cramer’s V) were 
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used (Appendix 9).  Participants were grouped into ≤5 years and >5 years experience in the Regulatory field.  All 
results showed that p>0.05, which means that there was no correlation between the desired review time for 
NCEs and generic applications when compared with the respondent’s years experience.  This was also observed 
in the Spearman's rho Correlation Coefficient, used to indicate the practical significance of the relationship or 
effect sizes: The correlation coefficient of years experience compared with the desired review time (minimum 
and maximum) for NCEs and generic product applications were -0.154, -0.180, and -0.103, demonstrating that a 
small and no practical significant relationship exists between the variables having a Correlation Coefficient value 
below 0.1. 
With the focus on the hypothesis, participants were asked if, in their opinion, by reducing the MRA’s burden in 
terms of performing full dossier reviews, the concept of TPA’s taking over the review process, will reduce the 
review time of applications from the date of submission to market approval.  88.5% (n=23) of the total 
participants (n=26) answered this question (Figure 18), of which all (100%) stated that the review time will 
decrease. 
 
Figure 18:  TPA reducing the review time of MA’s according to respondents (n=26) 
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The respondents’ feedback demonstrated that applicants were in favour of the TPA concept with 75% of the 
sample (n=12) being positive on the concept’s viability (Figure 16), and 82.6% of the sample (n=23) in favour of 
implementing a validated pilot project (Figure 17) of which 47.8% were confident that it can be fully 
implemented, assessing NCEs and generic dossiers for all categories as set out in the medicines and related 
substances act (Act 101 of 1965), where 34.8% supported a phased implementation, considering that the body 
consists of skilled and licensed members with a clear understanding of MRA’s aims and requirements for MAs.  
 
Figure 19:  The consideration of the viability of the TPA  
 
Figure 20: TPA pilot project implementation to be full or phased approach, or have the MCC continue 
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4.3 Triangulation 
 
The following variables were evaluated by means of theoretical and methodological triangulation: 
Time 
The results on investigating review times (the hypothesis’ dependant variable) were consistent across the three 
mixed-method analysis sections, with 86% of the investigated international health bodies and 75% of PPPs 
presented the benefit of reducing time spent, being coherent with the questionnaire feedback where 100% of 
the respondents affirmed that the TPA concept will reduce the review time for MAs.  
The optimal review time established from the questionnaire (which demonstrated that no practical significant 
relationship exists between the years experience and the optimal expected time, p>0.05) were 21 months (638 
days) for NCEs and 12 months (365 days) for generic applications (Figure 16 and 17).  When this was compared 
with the international health bodies, those with the disadvantage of an increased time were still within the 
desired optimal time of the respondents: GDUFA 10 months (304 days) and WHO PQP 4.3 months (131 days) for 
generics.  WHO PQP for NCEs were however outside this timeframe with 31.6 months (961 days).  Those bodies 
with the benefit of reduced review times were well within the expected time-frames. 
 From the results it was also evident that having pre-established timelines ensured realistic expectations, which 
are beneficial for the applicant, assessor and regulatory body monitoring the assessors.   
Skilled resources 
The benefit of reduced review times were not limited to an accelerated process for the specified product-review 
groups, but enabled more resources to be available within the NMRA to provide its critical functions.  NBs, 
GDUFA and WHO PQP were established for the purpose of increasing capacity in terms of regulatory human 
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resources.  The advantages in terms of increased resources and capacity for the international health bodies were 
applicable to 86% of those assessed.  This benefit was consistent with PPPs’ 67% increased resources. 
Each of the third party’s examined not only had criteria for designation, specified requirements and qualification 
standards, but the study also revealed that the partnership itself resulted in increased efficiency and 
performance, specialist-skill development, technological advance, innovation and continuous improvement, and 
superior outcomes, as well as satisfying regulatory requirements.  The collaborative strengths from each 
department are the cornerstone of this evolving asset to public health.  These factors together with PPPs benefit 
of added quality confirm that quality would not be compromised in the process of accelerated reviews. 
Transparency 
Transparency is fundamental in the regulatory sphere and a goal of the International Conference of 
Harmonisation.  Transparency is part of BEMA’s purposes and one of three main aims of GDUFA, improving MRA 
communication and feedback to accelerate access to medicines. Reasons for the current backlog from 
respondents included ambiguous regulatory feedback and guidelines.  In the ranking of TPA-operational qualities 
that would be imperative (with 10 being the maximum value), transparency had a mean of 8.83 and the second 
lowest standard deviation in the range with 2.289, showing that respondents concurrently and highly value 
transparency.  Although a benefit in both the international health bodies and PPPs, findings of transparency 
were inconsistent in terms of importance, revealing applicability to only 14% and 17% consecutively. 
Constant communication and bias 
Transparency raised the question if constant communication between the applicant, TPA and MRA would 
provide a solution, but the concern was that it may lead to bias.  82.6% of the respondents stated that the 
quality of the submissions will improve as a result of increased intercommunication, showing that a need exists 
for unambiguous and more frequent communication from the regulators and assessors.  Article 58 has pre-
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submission EMA meetings where applicants can obtain advice on procedures, legal and regulatory matters, to 
ensure MA conformance and to interact with assessors. With the highest standard deviation (3.5) in the 
feedback regarding the rating of constant communication, an inconsistency were revealed in the findings, and 
illustrated that there is an awareness of a fine line between increased communication and it affecting assessor 
judgement.   
Phased approach 
Respondents’ feedback on the implementation of a TPA showed that 47.8% were in favour of its full 
implementation, and 34.7% for a phased implementation.   In the question where participants rated the 
importance of the MRA still being responsible for handling expedited reviews, it had a high mean in relation to 
the ranking scale (7.35), yet a mean lower than the average mean in this 8-point question, and the second 
highest standard deviation (2.964), showing inconsistency.  When further triangulated with the international 
health bodies a trend is observed in support of a phased approach.  WHO’s PQP commenced with a focus on 
vaccines before expanding its scope to include medicines.  BEMA underwent phases in the form of cycles – the 
first establishing the methodology for benchmarking, the second focusing on assessments and organisation, and 
the third to include all medicine agencies.  NBs and APP are responsible for certain regulatory classes in the 
approval process, GDUFA focusing on generic product applications, and TA on generic products specific to 
PEPFAR.  From the results in analysing the concerns and disadvantages, process gaps and short-term rigidities 
may exist with the implementation of the new initiative, supporting a phased approach. 
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Chapter 5: Conclusions and Recommendations 
 
This research dissertation has given an account of and the reasons for the backlog and the protracted review 
times for MA assessments and approvals by the NMRA.  It has explained the central importance of constructing 
a partnership between the regulator and industry to solve complex issues by the collaboration of each sector’s 
specialists and resources, to be of benefit to the immediate population by increasing patient access. 
The aim of the study was to establish the need and to formulate a framework around the use of a TPA; to 
examine the advantages and possible disadvantages of the TPA concept in its purpose to decrease the NMRA’s 
burden and reduce the time between MA submission and approval, without compromising the quality of the 
assessment process.   
It can be concluded from the study that there will be a reduction in the time spent if a TPA is introduced, 
accepting or proving the hypothesis.  This was evident from the results during the evaluation of the international 
health models, PPPs and in the feedback from the participants.  The optimal review times confirmed by the 
participants were within the international review timelines for the partnership-entities investigated, thereby 
illustrating realistic expectations, and showed that no significant variance exists between the participant’s years 
experience and the optimal anticipated timeframes. The study suggests that pre-established review timelines 
and benchmarking are required to ensure realistic expectations for all concerned during the review process, to 
provide a tool for measuring outcomes and to identify gaps and areas of improvement to overcome unnecessary 
delays. 
The study has shown that a PPP makes skilled resources available to reduce the time spent on a project, e.g. 
dossier review, and further enables an increased capacity within the NMRA to perform its critical functions.  The 
TPA-concept was designed to reinforce that the final decision on MA approvals or rejections lies with the NMRA, 
while ensuring that ownership and accountability is maintained on both sides of the partnership.  This was also a 
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benefit observed for both the existing international health bodies assessed and the PPPs.   The qualitative arm of 
the study also found that the benefits are not restricted to better timelines and an increased capacity, but that 
efficiency, performance, skills, innovation, and superior outcomes increased as a result of a PPP. 
While this study revealed inconsistent findings when transparency, constant communication and bias were 
triangulated, it did substantiate that a need exists from the regulatory industry’s perspective for increased 
communication from the regulator, and that the quality of the submissions will increase as a result of 
transparency in requirements.   
Although an inconsistency in survey findings on the subject of a phased or full approach were observed for the 
implementation of the TPA, the qualitative arm of the study proved that challenges in the implementation phase 
can be addressed and overcome using a phased approach. 
The results from this research revealed that an improved strategy is needed and supports the concept of a TPA.  
The most important limitation to the study lies in the fact that theoretical problem solving was used and TPA 
remains a concept, which was evaluated in the light of similar concepts in existence such as international health 
bodies e.g. NBs, APPs etc. and PPPs. This form of extrapolation may proof to be inaccurate when applied in an 
actual setting.  Validation of the concept is therefore needed to assess its practicality and gaps that may exist in 
the concept.  This study was designed to introduce the concept of a TPA and investigate its effect on the MA 
review time, but further studies could assess the true cost implications and sustainability, the strategy and 
process that would be required to enable an effective implementation, TPA-staff criteria for designation and 
qualification standards, the contractual agreements that would be essential in this agreement, together with the 
stipulation of the benefit-risk responsibility.  As seen in this research, and an implication, is that a PPP needs to 
be incorporated into legislation, which will mean possible amendments to acts, regulations and guidelines.  It is 
worthy of noting that this is not impracticable or unattainable as it has been effectively implemented in other 
countries as proved in this research.  Participants of this study also considered TPA as a viable option. 
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Another limitation of the study was that the number of survey participants was very small and made use of 
convenience sampling.  This allowed the possibility of inaccurate assumptions and sampling errors as the 
participants may not necessarily be a true representation of the study population; in this research the target 
population was regulatory professionals from both industry and the NMRA.  The sample was more 
representative of the industry’s regulatory professionals, but no NMRA responses were received, which may 
increase biased survey conclusions.  The findings, analysis and discussion chapter did take this limitation into 
consideration and discussed the findings accordingly.  
Finally, a limitation when performing qualitative research is that primary data sources are not always readily or 
freely available.  The process of coding involves that categories are saturated after data collection and constant 
comparison were applied until the hypothesis can be tested.  This suggests that the accessibility to more or 
different primary sources may produce variations in findings.   
These study results and information can be used to develop targeted interventions aimed at providing lasting 
relief to the current review backlog, reducing the review time for MAs, while fulfilling its purpose of ensuring 
that medicine and medicinal products that approves of quality, safety and efficacy are available to patients and 
consumers. 
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The Impact 
An Accredited Third Party Assessor 
will have on the 
Regulator’s Response Time 
1.  Introduction 
Globally Medicine Regulatory Authorities (MRAs) have been under scrutiny for delayed Market Approvals, and 
have implemented different approaches to reduce consequential stakeholder tensions.  In South Africa MRA 
strategies have been beneficial in reducing the backlog, but a proactive approach is still needed to ensure 
sustainability, especially with rapid pharmaceutical and biopharmaceutical advances, and the newly released 
CAMS regulations.      
1.1 The Regulator’s Function 
The function of MRAs is to ensure the quality, safety and efficacy of medicine and medical devices, and promote 
health through “scientific excellence in the evaluation and supervision of medicines” (EMA, 2011: 30) by 
establishing a positive benefit-risk ratio.  This involves various elements as set out in Figure 1.  Regulators also 
have the responsibility of ensuring that medicines are made available to patients in a timely manner (Redmond, 
2004). 
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Figure 21: MRA Functions (Moran, 2010) 
Challenges in successfully fulfilling these functions and responsibilities exist such as limited human resources 
(and a high key-staff turnover); the need for public and financial support (especially for governmentally financed 
MRAs); more complex medicine and scientific advances; and often the quality of Market Applications (or 
dossiers) submitted that is sub-standard.  Stakeholder tensions increase as the review-times increase causing a 
delay in patient access (especially in illnesses where novel treatment is necessary, such as cancer and HIV/AIDS) 
and slowing pharmaceutical companies’ revenues.   A proactive approach, with a transparent methodology and 
tools that remain current, is required to regulate effectively (Lumpkin, 2012). 
1.2 Timelines and Backlogs experienced 
An international comparison on review-times showed that Switzerland’s IKS is one of the most efficient agencies 
(Vozeh, 1999), while the FDA and EMA are often under scrutiny for approval times (Roberts, 2011). 
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Figure 2: An overview of NCE review timelines for different MRAs  (Melchior, 2011) 
Severe delays were however caused by the MCC, which had sub-optimal registration timelines:  In 2008 the 
‘Backlog Project’ reduced the 4500 application-backlog (with submissions from 2001) to 1500 (by June 2010) by 
the Department for International Development’s (DFID) support (SARRAH, 2010).  In 2013, 26 evaluators were 
contracted to accelerate generic registration during the first quarter (SARRAH, 2013).  The backlog however is 
not cleared and an average of 48-52 month waiting period from first submission to registration still exists. 
1.3 Steps taken and Problem statement 
Some of the benefits of harmonization and the global use of CTD and eCTD are the increased transparency and 
reduced time in the review and approval process (Molzon, 2010).  In SA the pilot project for eCTD is in the final 
stages, but teething problems are experienced and more applicant training is needed.  The new regulatory body, 
SAHPRA, will have 400 instead of 150 members (Reuters, 2012), and the submission costs will increase, but the 
newly published CAMS guidelines (requiring a similar process as medicine approval) (MCC, 2013), and its local 
industry worth R2.5 billion (HPA, 2013) will necessitate increased and competent assessors.   
This leads to the problem of using a reactive approach by involving external reviewers, increasing funds needed, 
causing inconsistent reviews and uncertain review timeframes, which is not a sustainable long-term solution – a 
proactive approach is required. 
 
 
 
 
70 
 
 1.3.1 Research Question 
Will the MRA’s review time for Market Applications decrease if permanently appointed, competent Third Party 
Assessor are used, who are trained by an MCC/SAHPRA accredited trainer and program? 
 1.3.2 Hypothesis 
If MRAs make use of skilled Third Party Assessor, optimal review times for Market Applications will exist.   
2. Aim 
The aim of this study is to: 
 Formulate a framework around the use of Third Party Assessor;  
 Examine the benefits and possible drawbacks the concept of using accredited and competent Third Party 
Assessor will have on providing relief to the backlog currently experienced by SA’s MRA (MCC/SAHPRA), reduce 
the time between submission and approval, increase the quality of applications to the MCC and be of benefit to 
all associated stakeholders. 
 Establish a foundation for my anticipated doctorate in this subject, where the concept can be further explored 
and validated.    
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3. Limitations 
The limitation to the study lies in the fact that it remains a concept based on a combination of evaluations from 
similar global model-types (e.g. Notified Bodies – see section 4.4), extrapolating it to medicine and SA’s 
regulation; performing theoretical problem-solving.  Validation processes will be needed to assess the 
practicality and gaps of this initiative of introducing Third Party Assessor. 
4. Methodology 
4.1 Research design 
This dissertation will be a qualitative study exploring the variable’s significant facets such as scope of practice, 
bias, qualifications, processes, performance, etc. to structure this framework within the existing regulatory 
framework.   A concise quantitative survey will evaluate the industry’s receptiveness to the concept, producing a 
mixed method research approach.  Although this will not increase validation or generalization to the study, it will 
add richness to the data, testing the hypothesis (facilitation). 
4.2 Research subjects or participants 
As this is primarily a qualitative study, research subjects will not be involved.  The research will however have a 
small quantitative arm by using a short questionnaire.  This will be distributed to pharmacists in January 2014 to 
evaluate the susceptibility of the concept.  The questionnaire, not exceeding 10 questions, will contain a 
combination of closed and open-ended questions and will be designed in such a way that it will be submitted 
anonymously. The option of providing an email address will be presented, for the purpose of dissemination - 
should the participant wish to be informed of the questionnaire outcome.    
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Inclusion criteria: 
1. Pharmacists directly affected by registrations (Regulatory Affairs Pharmacists, Consultants, Quality  
             Assurance Pharmacists, Regulators and Inspectors); 
2. Non-pharmacists involved in the registration process. 
Exclusion criteria: 
1. Retail pharmacists; 
2. Other individuals not directly involved in the medicine registration process. 
4.3 Sample size 
For the quantitative survey, the sample size will depend on the amount of individuals willing to complete and 
submit the questionnaire.  It will therefore be a nonprobability sample, making use of convenience - and 
snowball samples.  This will limit the results in terms of generalization as it may not be a true representation of 
the specific population, but will give valuable feedback from pharmacists currently challenged with this problem 
in the industry.   
4.4 Study instruments, collection of data and analysis 
Qualitative data will be obtained from published literature (e.g. journals and regulations).  Theoretical sampling 
(from grounded theory) has already commenced by collecting data generating the theory.  This will further be 
used to collect more data, code and analyse the information during the process, leading towards the 
development and exploration of the theory.  Different aspects in this theory will be categorised using coding 
(open, axial and selective coding).  Using a conceptual analysis the relationship between equivalent international 
models will be assessed which include: 
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 Notified Bodies for medical devices (MHRA, 2013) 
 Third party Programs for medical devices (FDA CDRH, 2001)  
 Tentative approval (FDA, 2013) 
 Prequalification Programme (WHO, 2011) 
 ICH Global Cooperation Group (EMA, 2011)  
 European, TGA and Asian Benchmark Agencies (e.g. BEMA) (HMA, 2012) 
A quantitative survey (self-completion questionnaire) will be done via internet research methods using on-line 
tools such as SurveyMonkey™.  The pharmaceutical sector in South Africa, excluding retail, is small and the 
majority of industry pharmacists belong to an association accessible via an email-database, making it a 
representative sample. 
The objective of this meta-analysis will be to structure a strategy for using a Third Party Assessor, evaluating 
validity of arguments, performing a gap analysis and establishing general guidelines on how to introduce this 
concept into the existing regulatory framework. 
4.5 Gantt chart 
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4.6 Budget 
Financial resources for the qualitative study will not be required, as all data will be obtained from published 
literature.  In the event where articles need to be purchased to obtain more in-depth data, this will be self-
funded.  The quantitative arm of the study will also be done by via internet research methods using tools such as 
SurveyMonkey™ with minimal costs associated, that will be self-funded.    
5. Ethical Considerations 
No research subjects will be used. A succinct questionnaire will be completed voluntarily and anonymously, 
meaning that confidentiality and welfare will be respected.  See attached for the Ethics Forms. 
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Appendix 2  
MCC Structure 
MCC Structure: Pharmaceutical & Related Product Regulation & Management (MCC, 2003-2013) 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
Appendix 3  
TPA Organogram 
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Appendix 4  
TPA SOP for the procedure from dossier submission  
to final applicant communication 
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Appendix 5 
Email to industry 
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Appendix 6 
Survey/Questionnaire 
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Appendix 7  
Global MD review timelines*  
 
*  This table is a summary of the data obtained from the reference resource library for medical device regulatory process charts  
    and approval timelines (Emergo, 2014). 
 
 
 
 
Appendix 8 
FDA Accredited Persons Program review timelines (Hass, 2011) 
 
             
 
 
Medical device category Europe USA Canada Australia Costa Rica Taiwan South Korea Mexico Russia China Brazil Columbia Singapore Saudi-Arabia
Class I 2-4 2-4 4-5 1-2 14-15 11-12 5-10 / 18-36 1
Class I Exempt 1
Class I - Devices exempt from 510(k) process 1
Class I - Non-sterile, non-measuring 1 1
Class I - Sterile or measuring 3-5 2-3
Class II 2 2-4 8-17 1-2 17-30 5-10 / 18-36
Class IIa 1-3 2-3 12-17 14-15 1
Class IIb 2-6 2-3 14-15 4-7
Class II - or any device subject to 510(k) 3-6
Class II - Safety effectiveness Review 10-15
Class II or III - new/high risk 14-24
Class II - PMA or Class II devices without a predicate 18-30
Class III 7-9 4-5 7-14 2-8 7-9 14-15 17-36 18-36 4-7
Class III - Safety effectiveness Review 10-16
Class IV 6-8 2-10 7-9 18-36
Class IV - Safety effectiveness Review 10-15
Class A (sterile devices) 1-2
Class B 1-4
Class C 7-10
Class D 10-13
Low Risk 3-4 3-5
Medium Risk 3-5
High Risk 3-5
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Appendix 9 
GDUFA generic drug (ANDA) approval process (Uhl, 2013) 
 
 
Appendix 10 
Article 58 review time-lines (EMEA, 2009) 
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      Appendix 11 
Frequency tables to survey Question 6 
 
 
1: <1 year experience 
2: 1-5 years experience 
3: 6-10 years experience 
4: 10-15 years experience 
5: >15 years experience 
 
 
 
Frequency Percent Valid Percent
Cumulative 
Percent
1 3 13.0 13.0 13.0
2 14 60.9 60.9 73.9
3 3 13.0 13.0 87.0
4 1 4.3 4.3 91.3
5 2 8.7 8.7 100.0
Total 23 100.0 100.0
Valid
Experience
Frequency Percent Valid Percent
Cumulative 
Percent
1 1 4.3 4.3 4.3
2 2 8.7 8.7 13.0
5 1 4.3 4.3 17.4
7 1 4.3 4.3 21.7
8 4 17.4 17.4 39.1
9 3 13.0 13.0 52.2
10 11 47.8 47.8 100.0
Total 23 100.0 100.0
TPA_audited_annually
Valid
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Frequency Percent Valid Percent
Cumulative 
Percent
3 2 8.7 8.7 8.7
6 1 4.3 4.3 13.0
8 4 17.4 17.4 30.4
9 4 17.4 17.4 47.8
10 12 52.2 52.2 100.0
Total 23 100.0 100.0
Valid
Applicant_can_appeal_vs_TPA_decision
Frequency Percent Valid Percent
Cumulative 
Percent
2 1 4.3 4.3 4.3
3 1 4.3 4.3 8.7
4 1 4.3 4.3 13.0
5 1 4.3 4.3 17.4
6 2 8.7 8.7 26.1
8 4 17.4 17.4 43.5
9 1 4.3 4.3 47.8
10 12 52.2 52.2 100.0
Total 23 100.0 100.0
Rating_the_TPA_anonymously
Valid
Frequency Percent Valid Percent
Cumulative 
Percent
2 1 4.3 4.3 4.3
3 1 4.3 4.3 8.7
6 1 4.3 4.3 13.0
7 1 4.3 4.3 17.4
8 2 8.7 8.7 26.1
9 1 4.3 4.3 30.4
10 16 69.6 69.6 100.0
Total 23 100.0 100.0
Valid
Transparency
Frequency Percent Valid Percent
Cumulative 
Percent
1 1 4.3 4.3 4.3
3 2 8.7 8.7 13.0
7 1 4.3 4.3 17.4
8 1 4.3 4.3 21.7
10 18 78.3 78.3 100.0
Total 23 100.0 100.0
NDA
Valid
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Frequency Percent Valid Percent
Cumulative 
Percent
1 3 13.0 13.0 13.0
2 2 8.7 8.7 21.7
6 1 4.3 4.3 26.1
8 3 13.0 13.0 39.1
9 2 8.7 8.7 47.8
10 12 52.2 52.2 100.0
Total 23 100.0 100.0
Valid
Constant_communication
Frequency Percent Valid Percent
Cumulative 
Percent
1 1 4.3 4.3 4.3
2 1 4.3 4.3 8.7
3 1 4.3 4.3 13.0
5 1 4.3 4.3 17.4
6 1 4.3 4.3 21.7
8 2 8.7 8.7 30.4
9 3 13.0 13.0 43.5
10 13 56.5 56.5 100.0
Total 23 100.0 100.0
No_additional_costs
Valid
Frequency Percent Valid Percent
Cumulative 
Percent
1 1 4.3 4.3 4.3
2 2 8.7 8.7 13.0
5 4 17.4 17.4 30.4
6 2 8.7 8.7 39.1
8 3 13.0 13.0 52.2
9 2 8.7 8.7 60.9
10 9 39.1 39.1 100.0
Total 23 100.0 100.0
MCC_handling_expedited_reviews
Valid
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Appendix 12 
 Frequency tables for survey Question 10:  
Optimal and reasonable review times for NCEs and generic product market 
applications 
 
 
Frequency Percent Valid Percent
Cumulative 
Percent
3.00 1 3.8 5.3 5.3
6.00 3 11.5 15.8 21.1
9.00 1 3.8 5.3 26.3
12.00 3 11.5 15.8 42.1
16.00 1 3.8 5.3 47.4
18.00 2 7.7 10.5 57.9
24.00 4 15.4 21.1 78.9
36.00 3 11.5 15.8 94.7
62.00 1 3.8 5.3 100.0
Total 19 73.1 100.0
Missing System 7 26.9
26 100.0
Valid
Total
NCE_Min
Frequency Percent Valid Percent
Cumulative 
Percent
3.00 1 3.8 5.3 5.3
6.00 3 11.5 15.8 21.1
12.00 4 15.4 21.1 42.1
16.00 1 3.8 5.3 47.4
18.00 2 7.7 10.5 57.9
24.00 3 11.5 15.8 73.7
36.00 3 11.5 15.8 89.5
48.00 1 3.8 5.3 94.7
62.00 1 3.8 5.3 100.0
Total 19 73.1 100.0
Missing System 7 26.9
26 100.0
NCE_Max
Valid
Total
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Frequency Percent Valid Percent
Cumulative 
Percent
1 1 3.8 5.3 5.3
3 3 11.5 15.8 21.1
6 2 7.7 10.5 31.6
8 1 3.8 5.3 36.8
9 2 7.7 10.5 47.4
12 6 23.1 31.6 78.9
18 1 3.8 5.3 84.2
24 2 7.7 10.5 94.7
36 1 3.8 5.3 100.0
Total 19 73.1 100.0
Missing System 7 26.9
26 100.0
Gen_Min
Valid
Total
Frequency Percent Valid Percent
Cumulative 
Percent
1 1 3.8 5.3 5.3
3 3 11.5 15.8 21.1
6 2 7.7 10.5 31.6
8 1 3.8 5.3 36.8
9 2 7.7 10.5 47.4
12 6 23.1 31.6 78.9
24 3 11.5 15.8 94.7
36 1 3.8 5.3 100.0
Total 19 73.1 100.0
Missing System 7 26.9
26 100.0
Valid
Total
Gen_Max
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Appendix 13  
Crosstabs and correlations for survey Question 10 – 
assessing experience as a variable 
 
Nonparametric Correlations 
 
 
 
 
 
 
 
 
Experience NCE_Min NCE_Max Gen_Min Gen_Max
Correlation Coefficient 1.000 -.103 -.127 -.103 -.103
Sig. (2-tailed) .592 .509 .601 .600
N 26 19 19 19 19
Correlation Coefficient -.103 1.000 .968
**
.887
**
.879
**
Sig. (2-tailed) .592 .000 .000 .000
N 19 19 19 18 18
Correlation Coefficient -.127 .968
** 1.000 .902
**
.901
**
Sig. (2-tailed) .509 .000 .000 .000
N 19 19 19 18 18
Correlation Coefficient -.103 .887
**
.902
** 1.000 .993
**
Sig. (2-tailed) .601 .000 .000 .000
N 19 18 18 19 19
Correlation Coefficient -.103 .879
**
.901
**
.993
** 1.000
Sig. (2-tailed) .600 .000 .000 .000
N 19 18 18 19 19
Correlation Coefficient 1.000 -.154 -.180 -.103 -.103
Sig. (2-tailed) .529 .461 .676 .676
N 26 19 19 19 19
Correlation Coefficient -.154 1.000 .988
**
.949
**
.943
**
Sig. (2-tailed) .529 .000 .000 .000
N 19 19 19 18 18
Correlation Coefficient -.180 .988
** 1.000 .958
**
.958
**
Sig. (2-tailed) .461 .000 .000 .000
N 19 19 19 18 18
Correlation Coefficient -.103 .949
**
.958
** 1.000 .999
**
Sig. (2-tailed) .676 .000 .000 .000
N 19 18 18 19 19
Correlation Coefficient -.103 .943
**
.958
**
.999
** 1.000
Sig. (2-tailed) .676 .000 .000 .000
N 19 18 18 19 19
**. Correlation is significant at the 0.01 level (2-tailed).
Spearman's rho Experience
NCE_Min
NCE_Max
Gen_Min
Gen_Max
Correlations
Kendall's tau_b Experience
NCE_Min
NCE_Max
Gen_Min
Gen_Max
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Crosstabs 
Table 8: Experience grouped against the minimum desired time for NCEs 
 
 
 
 
 
 
 
 
 
 
 
1.00 2.00 3.00 4.00 6.00
Count 0 3 1 1 0 5
Expected Count 1.1 1.1 .8 1.1 .8 5.0
% within Experience_grouped
0.0% 60.0% 20.0% 20.0% 0.0% 100.0%
Count 4 1 2 3 3 13
Expected Count 2.9 2.9 2.2 2.9 2.2 13.0
% within Experience_grouped
30.8% 7.7% 15.4% 23.1% 23.1% 100.0%
Count 4 4 3 4 3 18
Expected Count 4.0 4.0 3.0 4.0 3.0 18.0
% within Experience_grouped
22.2% 22.2% 16.7% 22.2% 16.7% 100.0%
Total
Crosstab
NCE_min_grouped
Total
Experience_grouped >5
<=5
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 7.200
a 4 .126
Likelihood Ratio 8.454 4 .076
Linear-by-Linear Association
.479 1 .489
N of Valid Cases 18
Chi-Square Tests
a. 10 cells (100.0%) have expected count less than 5. The minimum expected count is .83.
Value Approx. Sig.
Phi .632 .126
Cramer's V .632 .126
18
Nominal by Nominal
N of Valid Cases
Symmetric Measures
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Table 9: Experience grouped against the maximum desired time for NCEs 
 
 
 
 
 
 
 
 
 
 
 
 
1.00 2.00 3.00 4.00 6.00 8.00
Count 0 3 1 1 0 0 5
Expected Count 1.1 1.1 .8 .8 .8 .3 5.0
% within Experience_grouped
0.0% 60.0% 20.0% 20.0% 0.0% 0.0% 100.0%
Count 4 1 2 2 3 1 13
Expected Count 2.9 2.9 2.2 2.2 2.2 .7 13.0
% within Experience_grouped
30.8% 7.7% 15.4% 15.4% 23.1% 7.7% 100.0%
Count 4 4 3 3 3 1 18
Expected Count 4.0 4.0 3.0 3.0 3.0 1.0 18.0
% within Experience_grouped
22.2% 22.2% 16.7% 16.7% 16.7% 5.6% 100.0%
Experience_grouped >5
<=5
Total
Crosstab
NCE_Max_grouped
Total
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 7.615
a 5 .179
Likelihood Ratio 9.133 5 .104
Linear-by-Linear Association
.734 1 .391
N of Valid Cases 18
a. 12 cells (100.0%) have expected count less than 5. The minimum expected count is .28.
Chi-Square Tests
Value Approx. Sig.
Phi .650 .179
Cramer's V .650 .179
18
Symmetric Measures
Nominal by Nominal
N of Valid Cases
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Table 10: Experience grouped against the minimum desired time for generic applications 
 
 
 
 
 
 
 
 
 
 
 
 
1.00 2.00 3.00 4.00 6.00
Count 1 3 0 0 0 4
Expected Count 1.3 1.9 .2 .4 .2 4.0
% within Experience_grouped
25.0% 75.0% 0.0% 0.0% 0.0% 100.0%
Count 5 6 1 2 1 15
Expected Count 4.7 7.1 .8 1.6 .8 15.0
% within Experience_grouped
33.3% 40.0% 6.7% 13.3% 6.7% 100.0%
Count 6 9 1 2 1 19
Expected Count 6.0 9.0 1.0 2.0 1.0 19.0
% within Experience_grouped
31.6% 47.4% 5.3% 10.5% 5.3% 100.0%
Total
Gen_Min_grouped
Total
Experience_grouped >5
<=5
Crosstab
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 1.953
a 4 .744
Likelihood Ratio 2.693 4 .610
Linear-by-Linear Association
.497 1 .481
N of Valid Cases 19
Chi-Square Tests
a. 9 cells (90.0%) have expected count less than 5. The minimum expected count is .21.
Value Approx. Sig.
Phi .321 .744
Cramer's V .321 .744
19
Nominal by Nominal
N of Valid Cases
Symmetric Measures
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Table 11: Experience grouped against the maximum desired time for generic applications 
 
 
 
 
1.00 2.00 4.00 6.00
Count 1 3 0 0 4
Expected Count 1.3 1.9 .6 .2 4.0
% within Experience_grouped
25.0% 75.0% 0.0% 0.0% 100.0%
Count 5 6 3 1 15
Expected Count 4.7 7.1 2.4 .8 15.0
% within Experience_grouped
33.3% 40.0% 20.0% 6.7% 100.0%
Count 6 9 3 1 19
Expected Count 6.0 9.0 3.0 1.0 19.0
% within Experience_grouped
31.6% 47.4% 15.8% 5.3% 100.0%
Experience_grouped >5
<=5
Total
Crosstab
Gen_Max_Grouped
Total
Value df
Asymp. Sig. (2-
sided)
Pearson Chi-Square 1.953
a 3 .582
Likelihood Ratio 2.693 3 .441
Linear-by-Linear Association
.583 1 .445
N of Valid Cases 19
a. 7 cells (87.5%) have expected count less than 5. The minimum expected count is .21.
Chi-Square Tests
Value Approx. Sig.
Phi .321 .582
Cramer's V .321 .582
19
Symmetric Measures
Nominal by Nominal
N of Valid Cases
 
 
 
 
